BDTX-189 receives FDA Fast Track Designation for solid tumors harboring HER2 or EGFR mutations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BDTX-189 has received Fast Track Designation from FDA for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 mutation or an epidermal growth factor receptor or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options.

BDTX-189, an orally available, irreversible small molecule inhibitor, is sponsored by Black Diamond Therapeutics, Inc. BDTX-189 is Diamond Therapeutics lead product candidate designed to selectively inhibit the activity of a broad range of previously unaddressed oncogenic driver mutations of the ErbB kinases in EGFR and HER2.

“While targeted therapies, such as kinase inhibitors, have transformed the treatment of cancer, only a small percentage of patients with metastatic cancer have tumors with genetic profiles that could make them eligible for an approved precision oncology medicine,” David M. Epstein, president and chief executive officer of Black Diamond Therapeutics, said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 
Silverstein during his surgical oncology fellowship, c. 1972This month on the Cancer History Project Podcast, Melvin J. Silverstein, Medical Director of Hoag Breast Center and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at USC, sat down with Stacy Wentworth, radiation oncologist and medical historian, to reflect on his career—and founding the first free-standing breast center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login